Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea · Delayed Price · Currency is KRW 34,350
-2,700 (-7.29%)
At close: Jul 28, 2026
Next Biomedical Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 16,825 | 16,477 | 9,543 | 4,882 | 2,795 | 2,267 |
Revenue Growth | 53.72% | 72.67% | 95.46% | 74.67% | 23.28% | 0.29% |
Gross Profit Gross Profit Growth | 11,793 | 11,449 | 5,755 | 2,069 | 177.49 | -731.09 |
Operating Income Operating Income Growth | -1,243 | -719.54 | -3,575 | -5,226 | -5,768 | -6,970 |
Net Income Net Income Growth | -36.35 | -311.08 | 2,860 | -7,522 | -5,732 | -16,645 |
Earnings Per Share EPS Growth | -4.46 | -38.27 | 397.00 | -1198.00 | -923.00 | -3440.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Endoscopic Hemostatic Agent Endoscopic Hemostatic Agent Growth | 8,256 | 4,269 | 2,005 | 1,018 |
Vascular Embolic Microspheres Vascular Embolic Microspheres Growth | 788.73 | 588.51 | 415.49 | 326.29 |
Vascular Embolic Microspheres -F Vascular Embolic Microspheres -F Growth | 489.21 | 14.23 | 4.4 | 6.4 |
Other Other Growth | 8.4 | 10 | 22.26 | 4.8 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 33,603 | 36,998 | 41,609 | 14,290 | 14,797 | 22,016 |
Total Debt Total Debt Growth | 7,425 | 7,712 | 10,949 | 11,519 | 11,017 | 31,751 |
Net Cash (Debt) Net Cash Growth | 26,178 | 29,286 | 30,659 | 2,771 | 3,780 | -9,735 |
Net Cash Growth | -14.61% | -4.48% | 1006.61% | -26.70% | - | - |
Net Cash Per Share Net Cash Per Share Growth | 3209.43 | 3603.03 | 4256.48 | 441.28 | 608.67 | -2011.96 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 358.2 | 1,250 | -1,201 | -4,160 | -8,208 | -5,396 |
Capital Expenditures CapEx Growth | -3,071 | -3,152 | -439.39 | -64.54 | -195.07 | -704.65 |
Free Cash Flow Free Cash Flow Growth | -2,713 | -1,902 | -1,640 | -4,225 | -8,403 | -6,101 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 70.09% | 69.49% | 60.31% | 42.38% | 6.35% | -32.25% |
Operating Margin | -7.39% | -4.37% | -37.46% | -107.05% | -206.37% | -307.42% |
Pretax Margin | -0.22% | -1.89% | 29.97% | -154.06% | -205.07% | -734.13% |
Profit Margin | -0.22% | -1.89% | 29.97% | -154.06% | -205.07% | -734.13% |
FCF Margin | -16.13% | -11.54% | -17.18% | -86.53% | -300.65% | -269.08% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 115.95 | - | - | - |
PS Ratio | 16.90 | 44.51 | 34.74 | - | - | - |